Enzalutamide
Treatment for Prostate Cancer
Typical Dosage: 160 mg once daily
Effectiveness
80%
Safety Score
55%
Clinical Trials
380
Participants
35K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
160 mg once daily
Time to Effect
1-3 months (PSA response)
Treatment Duration
Continuous until progression
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$2,000
Side Effect Mgmt:$800
Total Annual:$132,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$189,714
Comparison vs ADT alone
Cost Difference
+$126,800/year
More expensive
QALY Difference
+1.50 QALYs
Better outcomes
Dominance
No dominance
Enzalutamide Outcomes
for Prostate Cancer
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+70%
Common Side Effects
Fatigue/Asthenia
+40%
Hypertension
+18%
Hot flashes
+12%
Diarrhea
+12%
Headache
+10%
Falls
+10%
Seizures
+1%
Sources:
Active Clinical Trials
3 active trials recruiting for Enzalutamide in Prostate Cancer
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
NCT05204927ACTIVE NOT RECRUITINGPHASE3
439 participants
INTERVENTIONAL
Tucson, United States +51 more
Started: Feb 14, 2022
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
NCT03834493ACTIVE NOT RECRUITINGPHASE3
1.24K participants
INTERVENTIONAL
Mobile, United States +258 more
Started: Jul 28, 2019
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
NCT05743621RECRUITINGPHASE1
30 participants
INTERVENTIONAL
New York, United States
Started: Nov 20, 2023
Completed Clinical Trials
10 completed trials for Enzalutamide in Prostate Cancer
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
NCT03103724COMPLETEDPHASE2
68 participants
INTERVENTIONAL
Milan, Italy
Started: Mar 16, 2017
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
NCT01288911COMPLETEDPHASE2
375 participants
INTERVENTIONAL
Homewood, United States +87 more
Started: Mar 22, 2011
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer
NCT01565928COMPLETEDPHASE1
23 participants
INTERVENTIONAL
New York, United States +2 more
Started: Jan 24, 2012
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
NCT00510718COMPLETEDPHASE1
140 participants
INTERVENTIONAL
Boston, United States +8 more
Started: Jul 23, 2007
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
NCT01284920COMPLETEDPHASE1, PHASE2
47 participants
INTERVENTIONAL
Chugoku, Japan +6 more
Started: Nov 2, 2010
Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
NCT03927391COMPLETEDPHASE4
57 participants
INTERVENTIONAL
Nijmegen, Netherlands +2 more
Started: May 30, 2019
Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
NCT02453009COMPLETEDPHASE2
246 participants
INTERVENTIONAL
Trento, Italy
Started: Oct 1, 2014
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT02124668COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Tbilisi, Georgia +3 more
Started: Sep 23, 2014
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
NCT02204072COMPLETEDPHASE1
120 participants
INTERVENTIONAL
Detroit, United States +26 more
Started: Nov 11, 2014
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
NCT01302041COMPLETEDPHASE2
67 participants
INTERVENTIONAL
Brussels, Belgium +11 more
Started: May 6, 2011
Showing 20 of 389 total trials